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CPT-11 (irinotecan or 7-ethyl-10[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) is an anticancer agent in use for the
treatment of colon cancer. In order to be fully active, CPT-11 needs to be converted into SN-38 (7-ethyl-10-hydroxycamptothecin)
by the enzyme carboxylesterase (CE). In humans, only a minority of CPT-11 is converted to SN-38. To increase the antitumour effect
of CPT-11 by gene-directed enzyme prodrug therapy, we constructed a replication-deficient adenoviral vector Ad.C28-sCE2
containing a fusion gene encoding a secreted form of human liver CE2 targeted to the surface antigen epithelial cell adhesion
molecule (EpCAM) that is highly expressed on most colon carcinoma cells. By targeting CE2 to EpCAM, the enzyme should
accumulate specifically in tumours and leakage into the circulation should be minimised. Ad.C28-sCE2-transduced colon carcinoma
cells expressed and secreted active CE that bound specifically to EpCAM-expressing cells. In sections of three-dimensional colon
carcinoma spheroids transduced with Ad.C28-sCE2, it was shown that C28-sCE2 was capable of binding untransduced cells. Most
importantly, treatment of these spheroids with nontoxic concentrations of CPT-11 resulted in growth inhibition comparable to
treatment with SN-38. Therefore, Ad.C28-sCE2 holds promise in gene therapy approaches for the treatment of colon carcinoma.
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Conventional chemotherapy is not specific for tumour cells and
therefore its administration is limited by side effects. These side
effects might potentially be overcome by targeting chemotherapy
specifically to tumour cells by gene-directed enzyme prodrug
therapy (GDEPT). In GDEPT, a gene encoding a prodrug-
converting enzyme is delivered to the tumour by, for example,
an adenoviral vector. If the prodrug is administered it will be
specifically converted to the active drug at the site of the tumour.
This should increase the efficacy and decrease the side effects of
chemotherapy. CPT-11 (irinotecan or 7-ethyl-10[4-(1-piperidino)-
1-piperidino] carbonyloxycamptothecin) is an anticancer agent
that is approved for first-line treatment of metastatic colon cancer.
In order to be fully active, CPT-11 needs to be activated into
the active compound SN-38 (7-ethyl-10-hydroxycamptothecin) by
carboxylesterase (CE) enzymes (Tsuji et al, 1991; Satoh et al, 1994).
Although SN-38 is detected in the plasma of cancer patients only
minutes after administration of CPT-11 (Gupta et al, 1997),
90–95% of the prodrug is not converted to SN-38 (Rivory et al,
1997). A way to improve the antitumour effect of CPT-11 may be to
use CPT-11 and CE in a GDEPT approach. Adenoviral-mediated
expression of rabbit CE showed to sensitise efficiently a panel of
tumour cell lines to CPT-11 (Wierdl et al, 2001). A human enzyme,
however, has the advantage over a non-human enzyme that it will
not lead to an immune response against the enzyme and
subsequent enzyme inactivation. Kojima et al (1998) described
the construction of a replication-deficient adenoviral vector
containing the cDNA encoding human liver CE isoform 1 (CE1)
(Kojima et al, 1998). Cell lines transduced with this virus and
treated with CPT-11, however, showed only minimal antitumour
effects. The liver CE isoform 2 (CE2) has a higher affinity
and a higher conversion velocity of CPT-11 compared to CE1
(Humerickhouse et al, 2000). Therefore, we envisaged that human
liver CE2 would be the best candidate to employ in a GDEPT
approach to treat human colon cancer. Given the fact that current
gene transfer technologies do not allow transduction of all tumour
cells, a bystander effect is warranted to achieve effective kill of
untransduced tumour cells. To improve the bystander effect of
adenoviral vector-mediated GDEPT approaches, secreted and
surface-tethered prodrug-converting enzymes have been investi-
gated (Spooner et al, 2000; Weyel et al, 2000; Heine et al, 2001;
Oosterhoff et al, 2003). We envisioned that a targeted, secreted
form of CE2, consisting of the secreted form of CE2 (sCE2) fused to
a tumour-specific scFv antibody would provide an enlarged
bystander effect and would furthermore theoretically prevent
leakage of the protein into the circulation, thereby reducing
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ssystemic side effects. Previously, we constructed a fusion protein
in which sCE2 was fused to the human scFv antibody C28, which is
directed to the tumour antigen Epithelial Cell Adhesion Molecule
(EpCAM) (Oosterhoff et al, 2002). This fusion protein has
potential utility for GDEPT of colon cancer, because EpCAM is
highly overexpressed in colon cancer cells including distant
metastases (Litvinov et al, 1994). Here, we describe the construc-
tion of a replication-deficient adenoviral vector containing the
cDNA encoding the fully human fusion protein C28-sCE2. In a
three-dimensional tumour spheroid model in vitro, we could
demonstrate that the secreted fusion protein bound nontransduced
cells and caused efficient killing of colon cancer cells in the
presence of CPT-11.
MATERIALS AND METHODS
Cells and culture conditions
The colon cancer cell lines SW1398 and Colo205 and the ovarian
cancer cell line A2780 (all cell lines were kindly provided by Dr E
Boven, VUMC, Amsterdam, The Netherlands) were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% foetal calf serum (FCS), 50IUml
 1 penicillin and 50mgml
 1
streptomycin (Invitrogen, Breda, The Netherlands), at 371Ci na
5% CO2 humidified atmosphere. The 293 cell line (ATCC,
Manassas, VA, USA) was maintained in DMEM supplemented
with 10% FCS, 50IUml
 1 penicillin, 50mgml
 1 streptomycin and
2m ML -glutamine (Invitrogen).
Formation of colon cancer spheroids
In all 96-well plates (Greiner, Alphen aan den Rijn, The Nether-
lands) were coated with 2% agarose (Roche, Almere, The
Netherlands) in PBS. Colon cancer SW1398 or Colo205 cells were
plated (1 10
4 cellswell
 1) and rotated overnight at 140r.p.m. in a
Heidolph Unimax incubator. By plating equal amounts of cells in
each well and rotating them overnight, spheroids of similar sizes
are formed. This allows direct comparison of different treatment
modalities. After rotation, the formed spheroids were grown in a
5% CO2 humidified atmosphere at 371C for 3 days before use in
transduction experiments.
Construction of Ad.C28-sCE2
The adenoviral vector Ad.C28-sCE2 was constructed using the
AdEasy System (He et al, 1998). The plasmid pSTCF-C28-sCE2,
containing the secreted, EpCAM-targeted CE2 (C28-sCE2) open
reading frame (Oosterhoff et al, 2002) with a myc-6His tag at the
C-terminus, was digested with PmeI and NheI, and the C28-sCE2
open reading frame was ligated into the XbaI- and EcoRV-
linearised transfer vector pAdTrack-CMV. This construct contains
a gene encoding green fluorescent protein (GFP) under the CMV
promoter. Subsequently, the plasmid was digested with PmeI and
cotransformed into Escherichia coli BJ5183 cells with adenoviral
backbone plasmid pAdEasy-1 to construct pAdEasy-C28-sCE2.
After linearisation of this recombinant vector with PacI, the
plasmid was transfected into the 293 adenovirus packaging cell
line. Virus was further propagated in 293 cells according to
standard techniques. For all experiments, AdGFP (van Beusechem
et al, 2000) was taken along as a negative control.
Western blot analysis
Equivalent amounts of supernatant or cellular lysate from SW1398
cells transduced with Ad.C28-sCE2 were dissolved in sample buffer
(Laemmli, 1970) with 2-mercaptoethanol and heated to 951C for
5min. Samples were electrophoresed through a denaturing 10%
sodium dodecyl sulphate–polyacrylamide gel and protein bands
were electroblotted onto a PVDF protein membrane (BioRad,
Veenendaal, The Netherlands). Proteins were detected using anti-
myc antibody 9E10 (Chan et al, 1987) and HRP-conjugated rabbit
anti-mouse IgG (DakoCytomation, Heverlee, Belgium). Films were
developed with enhanced chemoluminescence (Lumilight Plus,
Roche, The Netherlands).
Esterase activity assay
To evaluate the esterase activity of proteins expressed by SW1398
cells transduced with Ad.C28-sCE2, cellular lysates or supernatants
were incubated with 200ml 100mM Tris-HCl (pH¼8.0) containing
1m M p-nitrophenyl-acetate (pNpAc) (Sigma Aldrich, Zwijndrecht,
The Netherlands), a substrate for CE. Conversion to pNp at room
temperature was measured during 10min using an ELISA plate
reader (BioRad) at a wavelength of 415nm.
Immunohistochemistry
Spheroids were harvested at different time points after transduc-
tion (day 1, 4 or 5) in TissueTek (Sakura Finetek, Zoeterwoude,
The Netherlands) and cryostat sections of 7–10mM were made and
stored at  801C. After drying, sections were fixed with 4%
formaldehyde in PBS for 30min, washed with PBS and treated with
0.2% Triton X-100 in PBS. After washing, the sections were
incubated for 1h with the anti-myc antibody 9E10. As a positive
control, anti-EpCAM antibody 323A3 (kindly provided by
Centocor, Leiden, The Netherlands) was taken along, and as
negative controls, PBS/0.1% BSA and anti-glucuronidase (Haisma
et al, 1995) were used. After incubation, sections were washed with
PBS and incubated with rabbit-anti-mouse-HRP or goat-anti-
rabbit-HRP (1:100 in PBS/0.1% BSA, both from DakoCytoma-
tion). After incubation for 1h, sections were washed with PBS and
stained with AEC (DakoCytomation) and sections were counter-
stained with haematoxylin.
In vitro cytotoxicity assays
At 3 days after the formation of colon cancer spheroids, the
spheroids were transduced with 1 10
7 plaque-forming units
(PFU) Ad.C28-sCE2 in 100ml culture medium. Control spheroids
were transduced with AdGFP or cultured in medium. After 7 days,
100ml culture medium was added containing a range of CPT-11
(Aventis, Strasbourg, France). After a further 7 days, cell viability
was determined by WST-1 (Roche Diagnostics) conversion at
371C. Data are expressed as percentages compared to untrans-
duced, untreated control spheroids.
RESULTS
Construction and characterisation of Ad.C28-sCE2
The open reading frame of C28-sCE2 with C-terminal mycHis-tag
was inserted in place of the E1 region of an adenovirus vector next
to a GFP expression cassette to create Ad.C28-sCE2 (Figure 1A).
SW1398 colon cancer cells were transduced with Ad.C28-sCE2
or control virus AdGFP at an MOI of 100 and after 6 days
expression of sCE2 in supernatant and cellular lysate was analysed
by Western blotting. Figure 1B shows that the majority of the
110kDa C28-sCE2 protein was detected in the supernatant of
Ad.C28-sCE2-transduced cells, confirming efficient secretion.
Enzyme activity of C28-sCE2 was demonstrated by an esterase
enzyme activity assay (Figure 1C). Binding of C28-sCE2 to
EpCAM-expressing cells was shown by immunohistochemistry
(Figure 1D). The EpCAM-positive cell line Colo205 and the
EpCAM-negative ovarian cancer cell line A2780 were incubated
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swith the supernatant of SW1398 cells transduced with Ad.C28-
sCE2 or AdGFP. As can be seen in Figure 1D, C28-sCE2 specifically
bound to the cellular membranes of EpCAM-expressing cells.
Diffusion of C28-sCE2 in multicellular colon cancer
tumour spheroids
Colo205 spheroids were transduced with Ad.C28-sCE2 and
cryosections were made 1, 4 and 5 days later. Sections were
stained with an anti-myc antibody to localise the C28-sCE2 fusion
protein. Figure 2 illustrates that on day 1 after transduction only
the outer rim of the spheroid stained slightly positive for C28-
sCE2. Sections of spheroids harvested at later time points after
transduction showed the presence of C28-sCE2 in deeper layers of
the spheroid. A higher magnification of the anti-myc staining
at day 5 after transduction (Figure 2B) suggests that C28-sCE2
had bound untransduced neighbouring cells since only the
cellular membrane of these cells stained positive. Thus, C28-
sCE2 penetrated into and accumulated in the tumour mass
surrounding Ad.C28-sCE2-transduced cells.
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Figure 1 Schematic structure of the replication-deficient adenovirus Ad.C28-sCE2 and characterisation of Ad.C28-sCE2-transduced SW1398 cells by
Western blot analysis, esterase activity assay and immunohistochemistry. (A) Schematic structure of the replication-deficient adenovirus Ad.C28-sCE2. The
C28-sCE2 expression cassette includes the CMV promoter, an IgGk leader sequence for secretion and a C-terminal myc- and His-tag for detection and
purification. The adenovirus also contains the gene encoding GFP under the CMV promoter. (B) Western blot analysis of cellular lysates (lanes 1 and 2) and
supernatants (lanes 3 and 4) of SW1398 cells transduced with Ad.C28-sCE2 (lanes 1 and 3) or AdGFP (lanes 2 and 4) at an MOI of 100. C28-sCE2 was
detected using an antibody directed to the myc-tag. (C) CE activity in cellular lysates and supernatants of SW1398 cells transduced with Ad.C28-sCE2 or
AdGFP at an MOI of 100. Cellular lysates or supernatants were incubated with 1mM pNpAc and conversion was measured during 10min. C28-sCE2
showed enzymatic activity and was efficiently secreted by transduced cells, since most of the activity was detected in the supernatant. (D) Binding of C28-
sCE2 to the EpCAM-expressing cell line Colo205. Colo205 cells or the EpCAM-negative cell line A2780 were incubated with the supernatant of SW1398
cells transduced with Ad.C28-sCE2 or AdGFP at an MOI of 100. After washing, the cells were stained with anti-myc antibody to show binding of C28-sCE2.
Only the EpCAM-expressing Colo205 cells incubated with supernatant of Ad.C28-sCE2-transduced SW1398 cells showed a positive membrane staining,
indicating that the fusion protein had bound specifically to the Colo205 cells.
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sCPT-11 activation and antiproliferative effects in
Ad.C28-sCE2-transduced cells
Colon cancer spheroids transduced with Ad.C28-sCE2 or AdGFP
were subjected to CPT-11 treatment for 7 days. Figure 3
demonstrated the viability of the spheroid as measured by WST-
1 conversion. Ad.C28-sCE2-transduced Colo205 and SW1398 colon
cancer spheroids were sensitised to CPT-11, since CPT-11
treatment to these spheroids was as toxic as treatment with its
activate analogue SN-38.
DISCUSSION
Targeting chemotherapy specifically to tumour cells with GDEPT
is expected to increase the antitumour effect, while side effects are
decreased. A limitation of adenoviral vector-mediated cancer gene
therapy is the poor penetration ability of adenoviral vectors into a
solid tumour mass. To improve the efficacy of adenoviral vector-
mediated GDEPT approaches, secreted prodrug-converting en-
zymes have been studied (Weyel et al, 2000; Oosterhoff et al, 2003).
However, secreted enzymes might leak away from the site of the
tumour. Therefore, cell surface-tethered forms of prodrug-
converting enzymes, such as b-glucuronidase or carboxypeptidase
G2, were developed to prevent leakage of untargeted enzyme from
the tumour, while prodrug activation is retained (Spooner et al,
2000; Heine et al, 2001). Another way to prevent diffusion of the
enzyme from the tumour is secretion by transduced tumour cells
of a fusion protein consisting of an scFv antibody and a prodrug-
converting enzyme, which can subsequently bind to tumour cells
(De Graaf et al, 2002; Oosterhoff et al, 2002). We hypothesised that
the bystander effect achieved by such a secreted targeted prodrug-
converting enzyme might be more pronounced than that achieved
by a cell surface-tethered form, as the targeted form can diffuse
and bind to neighbouring tumour cells. In this study, we
investigated the utility of a replication-deficient adenoviral vector
containing the cDNA encoding a secreted, EpCAM-targeted form
of human liver CE2, Ad.C28-sCE2, to sensitise colon cancer
tumours to CPT-11. We chose to study Ad.C28-sCE2 in a three-
dimensional in vitro colon cancer spheroid model, because the
three-dimensional structure of spheroids resembles in vivo
tumours much closer than two-dimensional cell cultures. Further-
more, we wanted to visualise the bystander effect by determining
secretion of C28-sCE2 and penetration of the fusion pro-
tein through a solid tumour mass, which can only be studied in
Figure 2 Immunohistochemistry on sections of Ad.C28-sCE2-transduced Colo205 spheroids. Colo205 spheroids were transduced with 1 10
7PFU
Ad.C28-sCE2 and harvested at day 1, 4 and 5 after transduction. Sections of these spheroids were made and stained for myc to detect C28-sCE2. (A)A t
day 1 after Ad.C28-sCE2 transduction, no positive staining can be detected. At days 4 and 5, several spots along the rim of the spheroid are positively
stained. (B) A higher magnification of the fusion protein staining at day 5 after transduction is shown. Cells with clear staining of membranes only (arrows)
represent untransduced neighbouring cells with bound C28-sCE2.
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sa three-dimensional structure. Grill et al demonstrated that
transduction of primary glioma spheroids with a replication-
deficient vector resulted in the expression of the transgene in the
outer rim of the spheroid only. This showed that spheroids are
relevant structures to study lack of adenovirus penetration into
solid tumour masses (Grill et al, 2002). In the colon cancer
spheroid model used in this study, we were able to detect the C28-
sCE2 fusion protein bound to untransduced cells several cellular
layers away from transduced cells. This suggests that C28-sCE2 is
capable of diffusing into a solid tumour mass.
From these results we hypothesised that optimal cytotoxicity
from CPT-11 could be expected if the prodrug was administered at
least a few days after Ad.C28-sCE2 transduction when C28-sCE2
has spread through the spheroid. Transduction of colon cancer
spheroids with Ad.C28-sCE2 and treatment with CPT-11 after 7
days resulted in complete sensitisation of these spheroids to CPT-
11. The toxicity to these spheroids was comparable to SN-38
treatment, indicating that CPT-11 is effectively converted into the
toxic drug.
In order to compare a targeted prodrug-converting enzyme with
a secreted prodrug-converting enzyme, it is necessary to perform
in vivo experiments. However, the high endogenous plasma
esterase activity in mice presents a challenge in using mouse
models to evaluate tumour-specific conversion of CPT-11. In mice,
more than 50% of the administered CPT-11 is converted to SN-38
by plasma esterases (Morton et al, 2000), whereas in human
patients less than 5% of the prodrug is activated (Rivory et al,
1997). Hence, the analysis of CE-mediated activation of CPT-11 in
normal mice does not accurately reflect what happens after the
administration of the drug to humans. Previously, a strain of
plasma esterase-deficient mice was described (Morton et al, 2000),
in which CPT-11 metabolism is comparable to that observed in
humans. Recently, these mice were crossbred with SCID mice
(personal communication with Dr Phil Potter, St Jude Children’s
Research Hospital, Memphis, USA) and we are currently testing
adenoviral vectors expressing EpCAM-targeted sCE2 or untargeted
sCE2 in these esterase-deficient SCID mice bearing colon cancer
xenografts.
In conclusion, we constructed a replication-deficient adenoviral
vector containing a cDNA encoding a secreted, EpCAM-targeted
form of human liver CE2 that was capable of converting the
prodrug CPT-11 into its activated form, leading to enhanced
toxicity of CPT-11 to colon cancer spheroids. Therefore, this
adenoviral construct holds promise in GDEPT approaches for the
treatment of patients with EpCAM-expressing colon cancer.
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